<DOC>
	<DOCNO>NCT02409472</DOCNO>
	<brief_summary>Dukes B2-C colorectal cancer patient evidence disease end front line treatment ( surgery adjuvant radio-chemotherapy , indicate ) eligible trial randomize two different surveillance program . These program differ greatly frequency diagnostic imaging . They similar schedule physical examination carcinoembryonic antigen ( CEA ) assessment . Patients receive baseline yearly health-related quality life ( HR-QoL ) questionnaires . Primary outcome overall survival QoL .</brief_summary>
	<brief_title>Intensive Versus Minimal Surveillance Patients With Resected Dukes B2-C Colorectal Carcinoma</brief_title>
	<detailed_description>Minimal program colon cancer : Office visit CEA 4,8,12,16,20,24,30,36,42,48 , 60 month . Colonoscopy 12 , 48 month . Liver echography* 8 , 20 month . Intensive program colon cancer : Office visit , CBC , CEA+CA 19.9 4,8,12,16,20,24,30,36,42,48 , 60 month . Colonoscopy 12 , 24 , 36 , 48 , 60 month . Liver echography* 4,8,12,16,24,36,48 , 60 month . Chest X-ray 12,24,36,48 , 60 month . * Abdominal-pelvis C.T. , alternative echography , 2° level exam ( doubtful result physical examination echography ; increase level CEA ; predictable poor sensitivity echography due obesity anatomic-clinical condition )</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>Patients histologically proven adenocarcinoma colon rectum Dukes AstlerColler modification stage B2C treat curative intent ( radical excision ± adjuvant radiochemotherapy ) . Eligible patient free know cancer prior study entry attest negative result endoscopy , liver ultrasonography , chest roentgenography serum CEA level perform &lt; 4 month randomization Inability undergo test ( disability , allergy contrast agent , etc . ) patient geographically amenable full followup . Patients enrol onto research protocol require strict adherence specific followup practice . A history previous malignancy last 10 year ( carcinoma situ cervix nonmelanoma skin cancer ) . No informed consent participate trial accord local regulatory guideline .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>randomize clinical trial</keyword>
</DOC>